The development of colorectal cancer (CRC) is not only a cause for significant concern for patients with ulcerative colitis and Crohn's disease, but is also one of the principal fears of gastroenterologists who care for these patients. The incidence of IBD-associated CRC is indeed decreasing over time as a likely consequence of the considerable efforts in recent decades directed at lowering CRC risk in patients with IBD [1] . Surveillance colonoscopy is often credited with this reduction, likely due to improvements at detecting and removing precancerous dysplastic lesions, particularly with the assistance of high definition and enhanced imaging technology. Other preventive measures that may have impacted CRC development include the long-term use of anti-inflammatory medications with putative chemopreventive activity, perhaps earlier surgical intervention, and improved understanding of risk factors such as histological inflammation, concomitant primary sclerosing cholangitis (PSC), and a family history of CRC, all of which may alter surveillance schedules. The ultimate goal is to avoid CRC, or at least detect it at the earliest stages associated with a higher probability of survival.
Despite these best efforts, however, patients with IBD still develop CRC. When this happens, data are conflicting as to whether their prognosis differs from those without IBD (sporadic CRC). In this issue of Digestive Diseases and Sciences, Samadder and colleagues queried datasets obtained from four different sources in the State of Utah: Intermountain Healthcare (IHC), The University of Utah Health Sciences (UUHSC), the Utah Cancer Registry (UCR), and the Utah Population Database (UPDB) from January 1996 to December 2011 to determine the prevalence, clinical features, and survival of IBD-associated CRC, compared to control patients with CRC who did not have IBD [2] . By identifying all patients in Utah with CRC, and cross-referencing this with a diagnosis of IBD, they identified 101 patients with IBD-CRC-representing 0.8% of all CRCs, a rate that is similar to previous studies. Patients with IBD-CRC were more likely to be younger, male, have concomitant PSC, and have cancer of the proximal colon compared to non-IBD-CRC. The major finding of the study was that patients with IBD-associated CRC had an inferior overall survival compared with those with sporadic CRC, after adjusting for age, sex, and tumor location. Nonetheless, it is worth noting that this observation was mainly driven by poorer survival among the 17 patients with advanced stage IBD-associated CRC-those with Stage I-III CRC had similar survival as controls.
The importance of this study is that very few studies have addressed the issue of CRC prognosis in IBD patients within the USA. Published studies either used Surveillance, Epidemiology, and End Results Program (SEER)-Medicare data [3] , or were based on referral center populations [4] . By linking a rather robust state cancer registry with other large databases, the investigators achieved what amounts to a population-based analysis of the problem, reinforced by their prior experience with these datasets, which increases confidence in the validity of their findings. They also took care to avoid including patients in whom the diagnosis of CRC preceded that of IBD. It is reassuring that they observed that CRC arose at a much younger age in the setting of IBD, which replicates practically all previous studies and likely reflects the observation that IBD predominantly afflicts young individuals. Somewhat puzzling, however, is that half of the CRC-IBD patients had their & Steven H. Itzkowitz steven.itzkowitz@mountsinai.org colitis for less than 4 years, when most studies indicate that it takes 7-10 years of colitis before the risk of CRC begins to rise. Despite the methodological strengths of this manuscript, with its cross-referenced databases, the lack of complete clinical and histopathological data ultimately leaves the reader uncertain as to the interpretation of the finding of poorer survival, leading to either speculation as to the reasons, or to indifference. It is not known whether a biologic phenomenon is responsible for this finding, or if the finding constitutes alpha error, even though the p value was \0.001 for an overall hazard ratio of 1.72. Alternatively, could it be that the patients with stage IV cancer did not receive full cancer treatment due to IBD severity or some other extenuating circumstance unrelated to the biology of the cancer itself? Either way, additional clinical, molecular and genetic studies within this population-based cohort are warranted to better understand these findings.
It is interesting, however, that disease stage distribution was proportionally similar between IBD and non-IBD patients, suggesting that colonoscopic screening and surveillance success (and failure) were similar in these two populations. Yet, without data regarding colonoscopy exposure, this is pure conjecture, and thus the nature of these failures is not clear. Did IBD-associated cancers develop in patients prior to initiation of screening and surveillance? The 45-month median colitis duration suggests that this might be the case. Were gastroenterologists recommending and carrying out surveillance according to recommended US society guidelines? How many of the advanced stage cancers were due to missed opportunities for surgical intervention, such as with the nonsurgical management of dysplasia? What about patient compliance with regular colonoscopies? Might some of these cancers be interval cancers? Indeed, using the same Utah databases, these investigators previously reported that patients with interval sporadic CRC had more proximal and earlier stage disease than those whose CRC was found on index colonoscopy [5] . If the differences in survival are related to the biology of the inflammation-induced cancer itself, do we know what percentage of cancers had microsatellite instability, a phenotype that is fairly common in IBD-CRC and is typically associated with improved survival.
For now, it remains unclear whether the survival of individuals with CRC-IBD is inferior to those with sporadic CRC. Studies like the present one provide interesting data upon which to build a more comprehensive biologic and molecular understanding of how colorectal neoplasia behaves in the setting of chronic IBD.
